BHI in Medical Science
Early Detection, Prevention, and Effective Therapies for Ophthalmic, Neurodegenerative, and Cardiovascular Disease — At present patients must wait months and in some cases even years for a definitive diagnosis of a serious neurodegenerative illness. Medical science is poised for a series of breakthroughs.
We have the knowledge and tools to design a panel of biomarkers, taking advantage of the fact that the eye, more specifically retinal ganglion cells, affords easy access to the central nervous system. It is a visible, safe, and measureable route to the brain. With new ophthalmic imaging technologies such as adaptive optics we are to take high resolution images of vascular impairment and mitochondrial dysfunction in a single neuronal cell instantaneously and non-invasively, and make accurate assessments without wasting precious time.
It is an axiom of modern neuropathology that neurons once lost do not grow back. Therefore time is exceedingly precious. In some instances patients’ conditions can become rapidly and irretrievably worse without early and effective intervention in a matter of months.
AFD has organized a Collaborative Innovation Network (COIN) ( the “Neurogenics Collaborative”) to accelerate the practical clinical applications of adaptive optics in combination with optical coherence tomography (OCT), focused beginning this summer of 2017 on early detection and prevention of glaucoma, diabetic neuropathy, macular degeneration, Alzheimer’s and Parkinson’s diseases, multiple sclerosis, ALS, hypertension, and stroke.
Participants in the COIN include pioneering inventors of the core technologies, innovators, and researchers at Stanford, UCLA, Oregon Health Science University, and Yale.
AFD’s mission is to deliver the benefits of the science and these ophthalmic technologies in the form of a simple, safe, and affordable test made available to the largest numbers of patients and their physicians around the world in the shortest period of time, at affordable cost. AFD has developed a humanitarian/business model that can deliver cash flow breakeven and financial self-sustainability by the end of Year 3.
AFD is currently seeking funding to support ongoing clinical studies and the collaborative development of a biomarker panel at Stanford, UCLA, Oregon Health Science University, and Yale.